Mymetics Corporation Now Blue Sky Registered in 44 States: Financial News

Mymetics Corporation Now Blue Sky Registered in 44 States
Wednesday September 24, 2008 8:30 am ET

NYON, Switzerland, Sept. 24, 2008 (GLOBE NEWSWIRE) -- Mymetics Corporation (OTC BB:MYMX.OB - News) (http://www.mymetics.com) announced today that its common stock has been Blue Sky registered for trading in 44 U.S. States with fully compliant filings submitted and awaiting imminent approval for the remaining (MI, MO, MN, NC, ND, TX) states. The company information is available via Standard & Poor's Market Access Program, and Standard & Poor's Advisor Insight. Standard & Poor's Advisor Insight is an Internet-based research engine used by more than 100,000 investment advisors and a public version of the site is available at http://www.advisorinsight.com.

In addition, information about companies in Standard & Poor's Market Access Program will be available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors. As part of the program, a full description of Mymetics Corporation will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under their Blue Sky Laws.

Mymetics has further contracted with BlueSkyMLS (http://www.blueskymls.com) to provide registration in states not covered by the S&P Market Access Program in order to complete their U.S. coverage.

About Mymetics Corporation

Mymetics' primary objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses and other infectious diseases, including the human immunodeficiency virus, or HIV, the virus that leads to acquired immunodeficiency syndrome, or AIDS. Mymetics has also recently acquired from a close scientific partner an advanced malaria vaccine project currently in phase Ib clinical trial. Additional applications of Mymetics' research include potential treatments and/or vaccines for human oncoviral leukemias, multiple sclerosis, and organ transplantation.